Ordinary Rebalance | Solactive Pharma Breakthrough Value Index | Effective Date 18th September 2023
In the ordinary rebalance, the following composition will be implemented effective open 18.09.2023:
| ALNYLAM PHARMACEUTICALS INC |
| ASTRAZENECA PLC-SPONS ADR |
| BEIGENE LTD-ADR |
| BIOCRYST PHARMACEUTICALS INC |
| BIOGEN INC |
| BIOMARIN PHARMACEUTICAL INC |
| BRISTOL-MYERS SQUIBB CO |
| CHUGAI PHARMACEUTICAL CO LTD ORD |
| EISAI |
| GENMAB A/S |
| HALOZYME THERAPEUTICS INC |
| HORIZON THERAPEUTICS PLC |
| INCYTE CORP |
| INNOCARE PHARMA LTD |
| INNOVENT BIOLOGICS INC |
| IONIS PHARMACEUTICALS INC |
| IPSEN SA |
| JAZZ PHARMACEUTICALS PLC |
| JCR PHARMACEUTICALS CO LTD |
| KYOWA KIRIN CO LTD |
| NIPPON SHINYAKU CO LTD |
| PHARMA MAR SA |
| PHARMING GROUP NV |
| PTC THERAPEUTICS INC |
| ROYALTY PHARMA PLC- CL A |
| SAREPTA THERAPEUTICS INC |
| SINO BIOPHARMACEUTICAL LTD ORD |
| SWEDISH ORPHAN BIOVITRUM AB |
| TAKEDA PHARMACEUTICAL |
| TRAVERE THERAPEUTICS INC |
| UNITED THERAPEUTICS CORP |
| VERTEX PHARMACEUTICALS INC |
| ZAI LAB LTD |